Trial Profile

A Clinical Trial to Evaluate the Impact of Broadly Neutralizing Antibodies VRC01LS and 10-1074 on Maintenance of HIV Suppression in a Cohort of Early-Treated Children in Botswana (Dual bNAb Treatment in Children)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 23 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Mar 2024 Results assessing findings for additional biomarker combinations, at entry to and during the bNAb-only step of the study, presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.
22 Feb 2023 Results presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023
15 Sep 2022 Results evaluating the safety and pharmacokinetics of dual intravenous VRC01LS and 10-1074 in very early-treated children with HIV-1, published in the JAIDS

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com